• Something wrong with this record ?

Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast

K. Hemminki, F. Tichanek, A. Försti, O. Hemminki, V. Liska, A. Hemminki

. 2022 ; 151 (4) : 510-517. [pub] 20220429

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22017780

Grant support
856620 Horizon 2020 Framework Programme

We analyzed long-term incidence trends in liver cancer (including hepatocellular carcinoma and intrahepatic cholangiocarcinoma) with an aim to interpret the changes in terms of known risk factors and hypothesize that historical exposure to Thorotrast, a radiographic contrast medium emitting alpha particles, has changed population rates. The NORDCAN database was used to collect cancer registry data from Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE), which we used from 1953 (DK, FI and NO) and 1960 (SE) through 2019. Thorotrast, which caused a 100-fold risk of liver cancer was used in DK and SE, and probably also in FI between 1930 and 1950, but not in NO. The incidence trend for liver cancer showed a broad maximum at around 1980, most prominent and statistically significant in SE and DK men and women, and in all countries, a steadily increasing trend towards the end of follow-up. Incidence for NO was lower than for the other countries and the rates showed no peaking at around 1980. Birth cohort analysis identified a transient risk which could be dated to a period between 1930 and 1950 in countries other than NO. Considering a lag time between Thorotrast use and liver cancer appearance, the large incidence peak around 1980 in DK and DE was probably contributed by Thorotrast but considering the ecological nature of the findings, the association should be considered cautiously as hypothesis generating. The late increase in liver cancer risk is most likely lifestyle related and largely preventable.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017780
003      
CZ-PrNML
005      
20220804134406.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.34031 $2 doi
035    __
$a (PubMed)35429352
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $1 https://orcid.org/0000000227693316
245    10
$a Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast / $c K. Hemminki, F. Tichanek, A. Försti, O. Hemminki, V. Liska, A. Hemminki
520    9_
$a We analyzed long-term incidence trends in liver cancer (including hepatocellular carcinoma and intrahepatic cholangiocarcinoma) with an aim to interpret the changes in terms of known risk factors and hypothesize that historical exposure to Thorotrast, a radiographic contrast medium emitting alpha particles, has changed population rates. The NORDCAN database was used to collect cancer registry data from Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE), which we used from 1953 (DK, FI and NO) and 1960 (SE) through 2019. Thorotrast, which caused a 100-fold risk of liver cancer was used in DK and SE, and probably also in FI between 1930 and 1950, but not in NO. The incidence trend for liver cancer showed a broad maximum at around 1980, most prominent and statistically significant in SE and DK men and women, and in all countries, a steadily increasing trend towards the end of follow-up. Incidence for NO was lower than for the other countries and the rates showed no peaking at around 1980. Birth cohort analysis identified a transient risk which could be dated to a period between 1930 and 1950 in countries other than NO. Considering a lag time between Thorotrast use and liver cancer appearance, the large incidence peak around 1980 in DK and DE was probably contributed by Thorotrast but considering the ecological nature of the findings, the association should be considered cautiously as hypothesis generating. The late increase in liver cancer risk is most likely lifestyle related and largely preventable.
650    12
$a nádory žlučových cest $x epidemiologie $7 D001650
650    _2
$a žlučové cesty intrahepatální $7 D001653
650    12
$a hepatocelulární karcinom $x chemicky indukované $x epidemiologie $7 D006528
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    12
$a nádory jater $x chemicky indukované $x epidemiologie $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    12
$a oxid thoričitý $x škodlivé účinky $7 D013911
651    _2
$a Dánsko $x epidemiologie $7 D003718
651    _2
$a Finsko $x epidemiologie $7 D005387
651    _2
$a Norsko $x epidemiologie $7 D009664
651    _2
$a Švédsko $x epidemiologie $7 D013548
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tichanek, Filip $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen $u Faculty of Medicine in Pilsen, Institute of Pathological Physiology, Charles University, Pilsen, Czech Republic
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Hemminki, Otto $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland $u Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
700    1_
$a Liska, Vaclav $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen $u Department of Surgery, University Hospital, School of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland $1 https://orcid.org/0000000171038530
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 151, č. 4 (2022), s. 510-517
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35429352 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134400 $b ABA008
999    __
$a ok $b bmc $g 1821742 $s 1169023
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 151 $c 4 $d 510-517 $e 20220429 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
GRA    __
$a 856620 $p Horizon 2020 Framework Programme
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options